Key New Finding in Study of Burkitt’s Lymphoma

According to a new study, new molecular insight into the treatment of Burkitt’s lymphoma may now be available. The hope is that these new findings will allow medical personnel to get a better understanding of how to treat one of the most vicious and aggressive tumors around.

As per the report, the specific emphasis of the research was placed on a genetic locus. This, of course, is a piece of DNA with one or multiple genes which is the location of a gene or DNA sequence on a given chromosome.

The particular locus in question encodes two vital tumor suppressor genes, p14 and p16. Further, it is usually canceled out in various tumors due to genetic mutations.

This research was conducted by the Sbarro Health Research Organizatio for Biotechnology. The nonprofit research center for cancer, cardiovascular and diabetes research is located in the College of Science and Technology at Temple University.

“We discovered a completely new mechanism for INK4/ARF protein inactivation,” said Annalisa Roberti, lead author of the paper. “Since in Burkitt`s lymphoma these two proteins are not inactivated at the genetic level, their inactivation could be pharmacologically reversible. The reactivation of p16 and p14 in our model and our ability to inhibit cell proliferation and induce apoptosis through the Rb- and p-53 pathways opens new prospects for the understanding and treatment of Burkitt’s lymphoma.”

“This is an additional piece of the complex puzzle in which the Rb family, which includes Rb2/p130, plays an important role. The new discovery in our laboratory presents additional evidence that more and more, Rb is becoming to be viewed as a guardian of our genome,” noted Antonio Giordano, M.D., Ph.D., Founder of SHRO and Director of the Sbarro Institute for Cancer Research and Molecular Medicine.

These latest findings are simply the first steps in a long process designed to help individuals suffering from Burkitt’s lymphoma.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap